Elicera Therapeutics Receives US Patent Allowance for CAR T-cell Candidate ELC-401
Elicera Therapeutics has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application covering the CAR T-cell candidate ELC-401.
Gothenburg, Sweden – Elicera Therapeutics, a cell and gene therapy company developing next-generation cancer treatments, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). This indicates the patent office's intent to grant a patent for the company's CAR T-cell candidate, ELC-401.
The patent application protects Elicera's specific antibodies designed to recognize and bind to a protein used in the ELC-401 therapy. The company views this allowance as a significant step in the development of ELC-401, strengthening its intellectual property portfolio and facilitating potential commercialization in the U.S. market.
ELC-401 is part of Elicera's pipeline of advanced CAR T-cell therapies. These therapies utilize the company's iTANK platform, which aims to enhance the T-cells' ability to activate the immune system against cancer cells. The company focuses on developing treatments for patients with limited therapeutic options.
Elicera Therapeutics is a clinical-stage company focused on therapies based on oncolytic viruses and CAR T-cells equipped with enhanced immune-activating properties.